People

Milestone Pharmaceuticals has announced the appointment of Joseph G. Oliveto as President and CEO. Oliveto, who was most recently CEO of Galleon Pharmaceuticals and previously served as President and CEO of Chelsea Therapeutics, is replacing company founder Phillippe Douville, who is now Chief Scientific Officer. Milestone's lead candidate, etripamil is an … [Read more...] about Milestone Pharmaceuticals appoints Joseph G. Oliveto as President and CEO

Intranasal drug developer Impel NeuroPharma has announced the appointment of former MAP Pharmaceuticals President and CEO Timothy S. Nelson as Independent Director of the Board of Directors. Nelson led MAP Pharmaceuticals when it was acquired by Allergan and served as Chairman of the Board of Civitas Therapeutics when that company was acquired by Acorda. MAP … [Read more...] about Timothy S. Nelson joins the board of Impel NeuroPharma

Lovelace Biomedical, a not-for-profit research organization which offers inhalation toxicology and other services for inhaled drug development, has announced the appointment of Larry Mallis as Director of Bioanalytical Operations. Mallis was most recently Director of Bioanalytical Services as Frontage Laboratories and was previously Director of Scientific Services … [Read more...] about Larry Mallis joins Lovelace Biomedical as Director of Bioanalytical Operations

OptiNose has announced that Keith A. Goldan has joined the company as Chief Financial Officer. Goldan was most recently Senior VP and CFO of Fibrocell and previously served as CFO at NuPathe, PuriCore (now Realm Therapeutics), and Biosyn. The announcement comes a few months after the company announced the appointment of Tom Gibbs as Chief Commercial Officer. In … [Read more...] about OptiNose appoints Keith A. Goldan as CFO

Smartinhaler maker Adherium has announced the appointment of former MicroDose Therapeutx co-founder Scott Fleming as Senior VP of Business Development, Europe, effective immediately. Fleming replaces John Tarplee who left the company at the end of 2016 "to pursue a new venture." After the sale of MicroDose Therapeutx to Teva in 2013, Fleming served as Senior … [Read more...] about Adherium appoints Scott Fleming as Senior VP of Business Development, Europe

OINDP development specialist Nanopharm has appointed Arron Danson as Head of Device Development, the company said. Danson has extensive experience in the development of pulmonary and nasal delivery devices, having worked at companies such as Vectura, Coalesce Product Development, and, most recently, Kinneir Dufort. Nanopharm, which announced the appointment of … [Read more...] about Nanopharm appoints Arron Danson as Head of Device Development

Avanir Pharmaceuticals, which launched its Onzetra Xsail intranasal dry powder sumatriptan in the US in May 2016, has announced the appointment of Richard Malamut as Senior VP, Research and Development and Chief Medical Officer. Malamut was most recently Senior VP of Global Clinical Development and Head of Pain, Oncology, Neuropsychiatry and NTEs at Teva … [Read more...] about Avanir appoints Richard Malamut Senior VP of R&D, CMO

Inhaled drug developer Savara Pharmaceuticals has announced the appointment of former Edgemont Pharmaceuticals CFO David L. Lowrance as its new Chief Financial Officer. Savara cited Lowrance's experience leading IPOs for Acucela, where he was CFO and Secretary, and Cumberland Pharmaceuticals, where he was VP and CFO. Savara Chairman and CEO Rob Neville commented, … [Read more...] about Savara Pharmaceuticals appoints David L. Lowrance as CFO

OptiNose has appointed Tom Gibbs as Chief Commercial Officer to oversee the commercialization strategy for EDS-FLU (OPN-375) intranasal fluticasone, which is in Phase 3 development for the treatment of nasal congestion in patients with nasal polyposis. Gibbs was most recently Senior VP and Head of the General Medicines Business Unit, US for Takeda. Gibbs said, “I … [Read more...] about OptiNose appoints Tom Gibbs as Chief Commercial Officer

Insmed has appointed Roger Adsett, a former global brand director for Symbicort, as its new Chief Commercial Officer in preparation for commercialization of Arikayce inhaled liposomal amikacin. Adsett also spent a portion of his time with AstraZeneca overseeing global marketing strategy for Rhinocort and Rhinocort Aqua. He was most recently Senior VP, Head of … [Read more...] about Insmed appoints Roger Adsett as Chief Commercial Officer